MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Buys 12,232 Shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA) by 10.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 126,380 shares of the biopharmaceutical company’s stock after acquiring an additional 12,232 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned approximately 0.06% of Akebia Therapeutics worth $240,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. SRS Capital Advisors Inc. purchased a new stake in Akebia Therapeutics in the 4th quarter worth approximately $26,000. Mariner LLC purchased a new stake in Akebia Therapeutics in the 4th quarter worth approximately $28,000. PDS Planning Inc purchased a new stake in Akebia Therapeutics in the 4th quarter worth approximately $28,000. Cibc World Markets Corp purchased a new stake in Akebia Therapeutics in the 4th quarter worth approximately $37,000. Finally, Aquatic Capital Management LLC purchased a new stake in Akebia Therapeutics in the 4th quarter worth approximately $47,000. 33.92% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on AKBA shares. Leerink Partners started coverage on Akebia Therapeutics in a report on Monday, April 28th. They issued an “outperform” rating and a $7.00 price objective for the company. Jefferies Financial Group started coverage on Akebia Therapeutics in a report on Tuesday, April 1st. They issued a “buy” rating and a $6.00 price objective for the company. Piper Sandler increased their price objective on Akebia Therapeutics from $4.00 to $6.00 and gave the stock an “overweight” rating in a report on Friday, March 14th. Wall Street Zen upgraded Akebia Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 3rd. Finally, HC Wainwright restated a “buy” rating and issued a $7.50 target price on shares of Akebia Therapeutics in a research note on Friday, April 4th. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $6.63.

Akebia Therapeutics Trading Up 0.7%

Shares of NASDAQ:AKBA opened at $3.03 on Monday. The stock has a fifty day simple moving average of $2.27 and a two-hundred day simple moving average of $2.09. The stock has a market capitalization of $795.79 million, a price-to-earnings ratio of -13.17 and a beta of 0.88. Akebia Therapeutics, Inc. has a 12-month low of $0.80 and a 12-month high of $3.14.

Akebia Therapeutics (NASDAQ:AKBA) last announced its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.06. The company had revenue of $57.34 million for the quarter, compared to analysts’ expectations of $44.88 million. As a group, equities research analysts predict that Akebia Therapeutics, Inc. will post -0.3 EPS for the current year.

Akebia Therapeutics Profile

Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.